SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-004697
Filing Date
2019-05-09
Accepted
2019-05-09 16:29:07
Documents
64
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20190331x10q.htm 10-Q 1766871
2 EX-31.1 crvs-20190331ex311245985.htm EX-31.1 13524
3 EX-31.2 crvs-20190331ex3123348bc.htm EX-31.2 13461
4 EX-32.1 crvs-20190331ex3218b001d.htm EX-32.1 13616
  Complete submission text file 0001558370-19-004697.txt   5729972

Data Files

Seq Description Document Type Size
5 EX-101.INS crvs-20190331.xml EX-101.INS 1139052
6 EX-101.SCH crvs-20190331.xsd EX-101.SCH 39624
7 EX-101.CAL crvs-20190331_cal.xml EX-101.CAL 53357
8 EX-101.DEF crvs-20190331_def.xml EX-101.DEF 105588
9 EX-101.LAB crvs-20190331_lab.xml EX-101.LAB 374784
10 EX-101.PRE crvs-20190331_pre.xml EX-101.PRE 259854
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 19810988
SIC: 2834 Pharmaceutical Preparations